Abbott Laboratories Q3 Adjusted Earnings, Sales Increase; 2026 Outlook Updated

08:05 AM EDT, 10/21/2026 (MT Newswires) -- Abbott Laboratories (ABT) reported Q3 adjusted earnings Wednesday of $1.42 per diluted share, up from $1.30 a year earlier. That matched the average estimate of analysts polled by FactSet. Sales for the quarter ended Sept. 30 was $13.01 billion, up from $11.37 billion a year earlier. Analysts expected $12.99 billion. For Q4, the company expects adjusted diluted EPS of $1.62 to $1.67. Analysts expect $1.64. For 2026, the company now expects adjusted diluted EPS guidance to between $5.50 and $5.55. That compares with the previous range of $5.45 to $5.60. Analysts expect $5.52. Sales for the year is now projected to grow around 6%, the company said. That compares with its previous guidance of 6.5% to 7.5%. Shares of the company were down nearly 5% in recent Wednesday premarket activity.